SCHEMBL6485162

SCHEMBL6485162

CC(C)(C)OC(=O)N1CCCN(c2cc3[nH]c(=S)[nH]c3cc2Cl)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.51
TSHR P16473 2/20 0.51
ALDH1A1 P00352 2/20 0.51
POLB P06746 2/20 0.51
KDM4E B2RXH2 1/20 0.51
GAA P10253 1/20 0.51
HPGD P15428 1/20 0.51
ALOX15 P16050 1/20 0.51
HSD17B10 Q99714 1/20 0.51
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
CKS1B P61024 1/20 0.41
SKP1 P63208 1/20 0.41
SKP2 Q13309 1/20 0.41
SUV39H2 Q9H5I1 2/20 0.41
CYBB P04839 1/20 0.40
NOX5 Q96PH1 1/20 0.40
NOX4 Q9NPH5 1/20 0.40
NOX1 Q9Y5S8 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6484073 0.95 MAPT (0.55) MAPTTSHRALDH1A1POLBKDM4E
SCHEMBL6492369 0.81 MAPT (0.55) MAPTTSHRALDH1A1POLBKDM4E
SCHEMBL6494859 0.81 MAPT (0.74) MAPTTSHRALDH1A1POLBKDM4E
SCHEMBL1902475 0.79 MEN1 (0.63) MAPTALDH1A1MEN1KMT2ACKS1B
SCHEMBL6495331 0.79 ALDH1A1 (0.52) MAPTTSHRALDH1A1POLBKDM4E
SCHEMBL6485470 0.78 ALDH1A1 (0.42) MAPTTSHRALDH1A1POLBKDM4E
SCHEMBL20158938 0.78 MEN1 (0.57) MAPTALDH1A1MEN1KMT2ACKS1B
SCHEMBL13419744 0.77 MEN1 (0.54) MAPTALDH1A1POLBKDM4EGAA
SCHEMBL6486955 0.76 OPRL1 (0.48) SUV39H2KCNH2
SCHEMBL6486948 0.76 NAMPT (0.45) POLBMEN1KMT2ACKS1BSKP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6969712-B2 Benzimidazole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-11-29 US disclosed
US-20040044056-A1 Benzimidazole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-03-04 US disclosed
EP-1342717-A1 BENZIMIDAZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-09-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044056-A1 Benzimidazole derivatives GPR119, OPRL1, INSR MAPT 400/4885TSHR 239/4885ALDH1A1 1851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.